Format

Send to

Choose Destination
Paediatr Respir Rev. 2011 Mar;12(1):22-6. doi: 10.1016/j.prrv.2010.09.005. Epub 2010 Oct 15.

Treatment of paediatric TB: revised WHO guidelines.

Author information

1
Centre for International Child Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia. steve.graham@rch.org.au

Abstract

The World Health Organization has recently revised the recommended dosages of the main first-line anti-tuberculosis drugs for use in children. The recommended dosages and range of isoniazid, rifampicin, pyrazinamide and ethambutol have been increased from the previous recommended dosages. Ethambutol is now recommended for use in children of all ages including those of less than 5 years of age. This review explains the rationale for these recent revisions. Children require higher dosages than adults to achieve the same serum concentrations. Available data in HIV-uninfected children suggest that the revised dosages are within limits that have a very low risk of toxicity. An important challenge will be to examine the impact of higher dosages on clinical response, drug-drug interactions and risk of toxicity in HIV-infected children.

PMID:
21172671
DOI:
10.1016/j.prrv.2010.09.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center